

The board of directors' proposal for a resolution on issue authorization (item 13 on the agenda in the notice of the Annual General Meeting on 21 May 2026)

The board of directors of Nanologica AB (publ), org. no. 556664-5023, (the "Company") proposes that the Annual General Meeting authorizes the board of directors to, during the period until the next Annual General Meeting, on one or more occasions, resolve on the issue of shares, convertibles and/or warrants.

The board of directors shall be able to resolve on an issue with or without deviation from the shareholders' preferential rights and with or without provision for contribution in kind and/or set-off or otherwise with conditions. In the case of issues carried out with deviation from the shareholders' preferential rights, the board of directors shall not be able to make decisions that entail that the amount by which the share capital is increased corresponds to more than twenty (20) percent of the total share capital in the Company prior to the completion of the issue.

An issue in accordance with this authorization shall be made on market terms. The board of directors shall be able to determine the terms and conditions for issues under this authorization and who shall have the right to subscribe for the shares, warrants, and/or convertibles. The reason why the board of directors shall be able to resolve on an issue with deviation from the shareholders' preferential rights and/or with provisions or conditions as set out above is that the Company shall be able to issue shares, warrants, and/or convertibles for the purpose of raising new capital and to enable the board of directors to direct issues to investors that the board of directors deems to be strategically important for the Company.

The board of directors, or a person appointed by the board of directors, shall have the right to decide on such minor changes to the resolutions of the Annual General Meeting as may be required upon registration of the resolution with the Swedish Companies Registration Office or due to other formal requirements.

A resolution in accordance with this proposal is subject to the support of shareholders representing at least two-thirds of both the votes cast and the shares represented at the Annual General Meeting.

Stockholm in April 2026
The board of Nanologica AB (publ)